Total Payments
$111,276
2024 Payments
$6,180
Companies
19
Transactions
142
Medicare Patients
1,066
Medicare Billing
$118,813
Payment Breakdown by Category
Consulting$63,823 (57.4%)
Travel$30,290 (27.2%)
Other$7,000 (6.3%)
Research$6,910 (6.2%)
Food & Beverage$2,803 (2.5%)
Education$450.73 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $63,823 | 25 | 57.4% |
| Travel and Lodging | $30,290 | 51 | 27.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,000 | 2 | 6.3% |
| Unspecified | $6,910 | 3 | 6.2% |
| Food and Beverage | $2,803 | 60 | 2.5% |
| Education | $450.73 | 1 | 0.4% |
Payments by Type
General
$104,366
139 transactions
Research
$6,910
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $42,029 | 71 | $0 (2020) |
| Gilead Sciences, Inc. | $14,575 | 16 | $0 (2019) |
| EMD Serono Research & Development Institute, Inc. | $12,160 | 4 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $11,158 | 12 | $0 (2018) |
| Bayer HealthCare Pharmaceuticals Inc. | $10,998 | 14 | $0 (2018) |
| Mallinckrodt Hospital Products Inc. | $7,720 | 3 | $0 (2024) |
| Mallinckrodt LLC | $4,389 | 5 | $0 (2018) |
| EMD Serono, Inc. | $2,400 | 2 | $0 (2021) |
| Theratechnologies Inc. | $2,000 | 1 | $0 (2021) |
| Abbott Laboratories | $1,500 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,180 | 3 | EMD Serono Research & Development Institute, Inc. ($6,160) |
| 2023 | $6,183 | 4 | EMD Serono Research & Development Institute, Inc. ($6,000) |
| 2022 | $750.00 | 1 | Ultragenyx Pharmaceutical Inc. ($750.00) |
| 2021 | $4,400 | 3 | EMD Serono, Inc. ($2,400) |
| 2020 | $9,700 | 4 | Mallinckrodt Hospital Products Inc. ($7,700) |
| 2019 | $16,492 | 23 | Gilead Sciences, Inc. ($13,261) |
| 2018 | $41,630 | 59 | AbbVie, Inc. ($19,505) |
| 2017 | $25,941 | 45 | AbbVie, Inc. ($17,343) |
All Payment Transactions
142 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/24/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: CRITICAL CARE | ||||||
| 03/11/2024 | EMD Serono Research & Development Institute, Inc. | — | — | Cash or cash equivalent | $1,320.00 | Research |
| Study: A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib Compared withTeriflunomide, in Participants with RelapsingMultiple Sclerosis to Evaluate Efficacy and Safety | ||||||
| 01/29/2024 | EMD Serono Research & Development Institute, Inc. | — | — | Cash or cash equivalent | $4,840.00 | Research |
| Study: A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib Compared withTeriflunomide, in Participants with RelapsingMultiple Sclerosis to Evaluate Efficacy and Safety | ||||||
| 11/11/2023 | Roche Products Limited | — | Food and Beverage | In-kind items and services | $73.00 | General |
| 05/07/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | — | Food and Beverage | In-kind items and services | $110.22 | General |
| 05/01/2023 | EMD Serono Research & Development Institute, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 04/10/2023 | EMD Serono Research & Development Institute, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 01/27/2022 | Ultragenyx Pharmaceutical Inc. | — | — | Cash or cash equivalent | $750.00 | Research |
| Study: UX701-CL301 | ||||||
| 06/04/2021 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 05/30/2021 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| 02/27/2021 | Theratechnologies Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 12/16/2020 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| 12/14/2020 | AbbVie Inc. | MAVYRET (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: VIROLOGY | ||||||
| 08/22/2020 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| 07/17/2020 | AbbVie Inc. | MAVYRET (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: VIROLOGY | ||||||
| 12/19/2019 | AbbVie, Inc. | Mavyret (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: Virology | ||||||
| 12/15/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $50.65 | General |
| Category: Virology | ||||||
| 12/15/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $50.65 | General |
| Category: Virology | ||||||
| 12/15/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $30.32 | General |
| Category: Virology | ||||||
| 12/15/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $25.66 | General |
| Category: Virology | ||||||
| 12/15/2019 | AbbVie, Inc. | Mavyret (Drug) | Travel and Lodging | In-kind items and services | $24.00 | General |
| Category: Virology | ||||||
| 11/19/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $109.00 | General |
| 11/19/2019 | Gilead Sciences, Inc. | — | Travel and Lodging | In-kind items and services | $60.00 | General |
| 11/19/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.41 | General |
| 11/09/2019 | F. Hoffmann-La Roche AG | — | Food and Beverage | In-kind items and services | $32.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase III, Multicenter, Randomized, ParallelGroup, Double Blind, Double Dummy, ActiveControlled Study of Evobrutinib Compared withTeriflunomide, in Participants with RelapsingMultiple Sclerosis to Evaluate Efficacy and Safety | EMD Serono Research & Development Institute, Inc. | $6,160 | 2 |
| UX701-CL301 | Ultragenyx Pharmaceutical Inc. | $750.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 252 | 288 | $161,311 | $27,627 |
| 2022 | 12 | 277 | 332 | $166,878 | $32,150 |
| 2021 | 10 | 248 | 296 | $150,014 | $29,215 |
| 2020 | 10 | 289 | 344 | $149,557 | $29,819 |
Total Patients
1,066
Total Services
1,260
Medicare Billing
$118,813
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 41 | 55 | $16,445 | $4,170 | 25.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 45 | 49 | $30,037 | $4,161 | 13.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 21 | 21 | $26,523 | $4,156 | 15.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 38 | 38 | $40,432 | $3,044 | 7.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 45 | $12,420 | $3,028 | 24.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $9,900 | $2,870 | 29.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 20 | 23 | $6,877 | $2,275 | 33.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $8,580 | $2,066 | 24.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 18 | $7,182 | $1,759 | 24.5% |
| 91200 | Measurement of liver stiffness | Facility | 2023 | 11 | 11 | $2,915 | $97.57 | 3.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 52 | 74 | $22,126 | $5,633 | 25.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 30 | 30 | $31,920 | $4,143 | 13.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 39 | 41 | $25,133 | $3,848 | 15.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 41 | $16,359 | $3,593 | 22.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 15 | 15 | $18,945 | $2,833 | 15.0% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 14 | 14 | $11,900 | $2,626 | 22.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 22 | $6,578 | $2,308 | 35.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 12 | 12 | $7,920 | $1,836 | 23.2% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 18 | 18 | $9,864 | $1,815 | 18.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 21 | 22 | $6,072 | $1,345 | 22.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 11 | 11 | $5,577 | $974.30 | 17.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 14 | 14 | $2,702 | $744.37 | 27.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 15 | 18 | $1,782 | $452.84 | 25.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 45 | 58 | $17,342 | $4,712 | 27.2% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 30 | 30 | $31,920 | $4,166 | 13.1% |
About Dr. Paul Martin, MD
Dr. Paul Martin, MD is a Gastroenterology healthcare provider based in West Hollywood, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184642910.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Martin, MD has received a total of $111,276 in payments from pharmaceutical and medical device companies, with $6,180 received in 2024. These payments were reported across 142 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($63,823).
As a Medicare-enrolled provider, Martin has provided services to 1,066 Medicare beneficiaries, totaling 1,260 services with total Medicare billing of $118,813. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Hepatology, Hepatology
- Location West Hollywood, CA
- Active Since 07/18/2006
- Last Updated 06/27/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1184642910
Products in Payments
- Nexavar (Drug) $10,998
- Mavyret (Drug) $8,753
- Viekira (Drug) $8,529
- Epclusa (Drug) $7,716
- ZEPATIER (Drug) $4,974
- MAVYRET (Drug) $2,000
- Architect system (Device) $1,500
- Manometry (Device) $1,000
- OCALIVA (Drug) $128.95
- THERASPHERE - BIO (Device) $122.12
- XIFAXAN (Drug) $69.79
- MENACTRA (Drug) $42.29
- TERLIVAZ (Drug) $19.94
- ADACEL (Drug) $17.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in West Hollywood
Maria Abreu, M.d, M.D
Gastroenterology — Payments: $521,475
Gastroenterology $521,475
Walid Ayoub, M.d, M.D
Gastroenterology — Payments: $340,991
Gastroenterology $340,991
Dr. Dermot Mcgovern, M.d., Ph.d., Mrcp, M.D., PH.D., MRCP
Gastroenterology — Payments: $140,154
Gastroenterology $140,154
Dr. Kenneth Park, M.d., M.sc, M.D., M.SC
Gastroenterology — Payments: $45,086
Gastroenterology $45,086
Ju Dong Yang, Md, MD
Gastroenterology — Payments: $37,270
Gastroenterology $37,270
Alexander Kuo, M.d, M.D
Gastroenterology — Payments: $33,911
Gastroenterology $33,911